Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Market Cap: US$43.7b

Teva Pharmaceutical Industries Future Growth

Future criteria checks 4/6

Teva Pharmaceutical Industries is forecast to grow earnings and revenue by 28.8% and 3% per annum respectively. EPS is expected to grow by 31.7% per annum. Return on equity is forecast to be 34.8% in 3 years.

Key information

28.8%

Earnings growth rate

31.73%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate3.0%
Future return on equity34.78%
Analyst coverage

Good

Last updated20 Aug 2026

Recent future growth updates

Recent updates

Seeking Alpha • Aug 03

Teva's Re-Rating Still Has Room To Run

Summary Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026. I maintain a Buy rating, as TEVA still trades below sector multiples and further upside is possible if specialty growth and margin targets are met. Read the full article on Seeking Alpha
Narrative Update • Jul 21

TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion

Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries from about $21.53 to roughly $33.08, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples, along with recent price target increases across several firms and renewed confidence in the vitiligo program despite short term share price weakness. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries has centered on how investors should think about valuation relative to execution risk, particularly around the vitiligo program and the timing of clinical milestones.
Narrative Update • Jul 07

TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries from $45.00 to about $48.72, citing updated assumptions around revenue growth, profit margins, and future P/E. These changes align with a series of recent price target increases across the Street.
Narrative Update • Jun 23

TEVA: Neuroscience Pivot And Vitiligo Readout Timing May Support 2026 Repricing

Teva Pharmaceutical Industries' analyst price target has been adjusted slightly to $40.90, with analysts pointing to recent stock underperformance tied to macro factors and updated vitiligo trial timelines, while maintaining underlying confidence in the pipeline and business fundamentals. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries highlights a mix of optimism about the company’s pipeline execution and caution around near term headlines and timing.
Analysis Article • Jun 21

Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after a recent share price pullback, with the stock closing at $31.48. Investors are assessing how the current valuation lines up with the company’s fundamentals. See our latest analysis for Teva Pharmaceutical Industries. The recent 7 day share price return, down 9.1%, and 1 month share price return, down 7.6%, contrast with a 1 year total shareholder return of 85.7% and 3 year total shareholder return above 3x. This suggests that...
Narrative Update • Jun 08

TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal

Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.
Narrative Update • May 25

TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal

Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.
Narrative Update • May 04

TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal

Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.
Narrative Update • Apr 16

TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal

Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.
New Narrative • Apr 09

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?
Narrative Update • Apr 02

TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal

Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.
Narrative Update • Mar 18

TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook

Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.
Narrative Update • Mar 04

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.
Narrative Update • Feb 18

TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook

Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.
Narrative Update • Feb 04

TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook

Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.
Narrative Update • Jan 20

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating

Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.
Narrative Update • Jan 06

TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.
Narrative Update • Dec 22

TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.
Narrative Update • Dec 08

TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins

Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.
Narrative Update • Nov 24

TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches

Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.
Analysis Article • Nov 13

We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative

Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...
Analysis Article • Nov 12

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...
Narrative Update • Nov 07

TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears

Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.
Narrative Update • Oct 23

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.
Narrative Update • Oct 09

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.
Narrative Update • Sep 25

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
User avatar
New Narrative • Apr 23

Generics And Biosimilars Pipeline And Expansion Will Define Progress

The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.
Seeking Alpha • Feb 28

Teva Pharmaceutical: A Risky Bet With Potential Upside

Summary Teva Pharmaceutical faces challenges with high debt, legal issues, and pricing pressure, but is shifting focus to higher-margin biosimilars and specialty drugs. Despite trading at a low 6.56x forward earnings, Teva's high debt-to-EBITDA ratio and declining earnings are significant concerns. The company's push into biosimilars is promising, but execution and market competition will be critical for success. Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and profitability issues. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:TEVA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202818,0562,7273,8933,1308
12/31/202717,3042,3373,1932,63210
12/31/202616,5821,1402,1941,5119
6/30/202617,3157061,3471,898N/A
3/31/202617,3491,5651,1721,714N/A
12/31/202517,2581,4101,1481,649N/A
9/30/202516,7767135781,066N/A
6/30/202516,628-1578901,390N/A
3/31/202516,616-1,2867651,266N/A
12/31/202416,544-1,6397491,247N/A
9/30/202416,772-9591,3681,856N/A
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3366081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825N/A941N/A
12/31/201916,887-999N/A748N/A
9/30/201916,396-4,048N/A577N/A
6/30/201916,831-4,007N/A673N/A
3/31/201917,355-3,559N/A1,062N/A
12/31/201818,271-2,399N/A2,446N/A
9/30/201819,693-11,059N/A2,938N/A
6/30/201820,781-10,256N/A3,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TEVA's forecast earnings growth (28.8% per year) is above the savings rate (3.7%).

Earnings vs Market: TEVA's earnings (28.8% per year) are forecast to grow faster than the US market (16.9% per year).

High Growth Earnings: TEVA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TEVA's revenue (3% per year) is forecast to grow slower than the US market (12.9% per year).

High Growth Revenue: TEVA's revenue (3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TEVA's Return on Equity is forecast to be high in 3 years time (34.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/20 03:05
End of Day Share Price 2026/08/20 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Teva Pharmaceutical Industries Limited is covered by 44 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Glen SantangeloBarclays